Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

[1]  D. Boyd,et al.  Regulation of matrix metalloproteinase gene expression , 2007, Journal of cellular physiology.

[2]  Susanna M. Grzeschik,et al.  Neurodegeneration in Striatum Induced by the Mitochondrial Toxin 3-Nitropropionic Acid: Role of Matrix Metalloproteinase-9 in Early Blood-Brain Barrier Disruption? , 2003, The Journal of Neuroscience.

[3]  Norman Relkin,et al.  Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease , 2003, Neurochemistry International.

[4]  E. Hirsch,et al.  The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[5]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[6]  B. Volpe,et al.  Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice , 2003, Brain Research.

[7]  S. Loening,et al.  Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats , 2003, The Prostate.

[8]  猪原 匡史.  Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter , 2003 .

[9]  S. Lorenzl,et al.  Expression of MMP-2, MMP-9, and MMP-1 and Their Endogenous Counterregulators TIMP-1 and TIMP-2 in Postmortem Brain Tissue of Parkinson's Disease , 2002, Experimental Neurology.

[10]  Jiankun Cui,et al.  S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death , 2002, Science.

[11]  M. Fini,et al.  Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. , 2002, Journal of neurotrauma.

[12]  L. Kaczmarek,et al.  Matrix Metalloproteinase-9 Undergoes Expression and Activation during Dendritic Remodeling in Adult Hippocampus , 2002, The Journal of Neuroscience.

[13]  M. Beal,et al.  Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease , 2001, The Journal of Neuroscience.

[14]  S. Itohara,et al.  Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia , 2001, Neuroreport.

[15]  E. Hirsch,et al.  Caspase‐3 activation in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated mice , 2001, Movement disorders : official journal of the Movement Disorder Society.

[16]  T. Hattori,et al.  Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. , 2001, Clinical neuropathology.

[17]  P. Gottschall,et al.  Regional and age-related expression of gelatinases in the brains of young and old rats after treatment with kainic acid , 2000, Neuroscience Letters.

[18]  F. Weber,et al.  Matrix metalloproteinase‐9 is elevated in serum of patients with amyotrophic lateral sclerosis , 2000, Neuroreport.

[19]  C. Morris,et al.  Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease , 2000, Neuroscience Letters.

[20]  R. Scott,et al.  MPTP Activates c‐Jun NH2‐Terminal Kinase (JNK) and Its Upstream Regulatory Kinase MKK4 in Nigrostriatal Neurons In Vivo , 2000, Journal of neurochemistry.

[21]  T. Hattori,et al.  Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain , 2000, Acta Neuropathologica.

[22]  M. Fujimura,et al.  Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemia and reperfusion , 1999, Brain Research.

[23]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[24]  P. Gottschall,et al.  Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration , 1998, The European journal of neuroscience.

[25]  J. Penney,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2 , 1998, The Journal of Neuroscience.

[26]  S. Lorenzl,et al.  Matrix metalloproteinases contribute to the blood—brain barrier disruption during bacterial meningitis , 1998, Annals of neurology.

[27]  M. Beal,et al.  Excitotoxicity and nitric oxide in parkinson's disease pathogenesis , 1998, Annals of neurology.

[28]  M. Mass,et al.  The MAP Kinase Cascade Is Activated prior to the Induction of Gliosis in the 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) Model of Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.

[29]  M. Fini,et al.  Regulation of Matrix Metalloproteinase Gene Expression , 1998 .

[30]  J. O'Callaghan,et al.  The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity. , 1998, Annals of the New York Academy of Sciences.

[31]  A. Clark,et al.  Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.

[32]  K. Nishi.  Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice , 1997, Brain Research.

[33]  P. Gottschall,et al.  Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification , 1997, Journal of Neuroscience Methods.

[34]  C. Miller,et al.  Matrix Metalloproteinases in the Neocortex and Spinal Cord of Amyotrophic Lateral Sclerosis Patients , 1996, Journal of neurochemistry.

[35]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[36]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[37]  S. Zucker,et al.  Localization of Tissue Inhibitor of Matrix Metalloproteinases in Alzheimer's Disease and Normal Brain , 1995, Journal of neuropathology and experimental neurology.

[38]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[39]  H. Nagase.  Matrix metalloproteinases. A mini-review. , 1994, Contributions to nephrology.

[40]  G. Opdenakker,et al.  Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein , 1993, Journal of neuroscience research.

[41]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[42]  Miki Hasegawa,et al.  A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor , 1993, Nature.

[43]  A. Duchemin,et al.  c-fos mRNA in mouse brain after MPTP treatment , 1992, Neurochemistry International.

[44]  Richard E. Coggeshall,et al.  A consideration of neural counting methods , 1992, Trends in Neurosciences.

[45]  R. Kurlan,et al.  The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐tetrahydropyridine to monkeys , 1991, Annals of neurology.

[46]  I. Date,et al.  Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis , 1990, Brain Research.

[47]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.